NDC product
RELAFEN DS
NDC 15370-170 · Carwin Pharmaceutical Associates, LLC
Key facts
| Product NDC | 15370-170 |
|---|---|
| Proprietary name | RELAFEN DS |
| Nonproprietary name | NABUMETONE |
| Substances | NABUMETONE |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Carwin Pharmaceutical Associates, LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA203166 |
| Pharmacologic classes | Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC] |
| Marketing start | Sep 20, 2019 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: